BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
OMER upcoming catalysts
Omeros Corporation: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 1 FDA event(s). Subscribe to OMER (.ics).
Drugs: OMS906
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Omeros Corporation OMER | NCT06298955 Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | active not recruiting | 25 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2025-12-23 | FDA approval | approved | OMEROS CORP OMER | YARTEMLEA | Approved 2025-12-23: YARTEMLEA (BLA761152 ORIG1) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-04-14 | P2 | Omeros Corporation OMER | NCT06209736 Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN | C3 Glomerulopathy; Idiopathic Immune Complex-Mediated Glomerulonephritis | terminated | 3 |
| 2025-12 est. | P2 | Omeros Corporation OMER | NCT05855083 Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA | Thrombotic Microangiopathies; Hematopoietic Stem Cell Transplantation | recruiting | 18 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.